H. Hurwitz

A phase I study of XL228, a potent IGF1R/AURORA/SRC inhibitor, in patients with solid tumors or hematologic malignancies

David C. Smith, Carolyn D. Britten, D O Clary et al. · Journal of Clinical Oncology · 2009 · 26 citations

Medicine, Oncology, Pharmacology +17

A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently

Maja J.A. deJonge, S. Savage, Jaap Verweij et al. · Journal of Clinical Oncology · 2006 · 22 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +13

Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors

H. Hurwitz, Barbara Scott Nelson, P J O'Dwyer et al. · Journal of Clinical Oncology · 2008 · 16 citations

Medicine, Oncology, Pharmacology +14

Clinical summary of 67 heavily pre-treated patients with metastatic carcinomas treated with GW572016 in a phase Ib study

E. Claire Dees, H. Burris, H. Hurwitz et al. · Journal of Clinical Oncology · 2004 · 15 citations

Medicine, Oncology, Pharmacology +17

Phase I dose-escalation study of the anti-VEGFR-2 recombinant human IgG1 MAb IMC-1121B administered every other week (q2w) or every 3 weeks (q3w) in patients (pts) with advanced cancers

Elena G. Chiorean, Christopher Sweeney, H. Hurwitz et al. · Molecular Cancer Therapeutics · 2007 · 12 citations

Medicine, Oncology, Pharmacology +11